NervGen Pharma Corp.: NervGen Pharma Grants Stock Options
Vancouver, British Columbia (Newsfile Corp. - July 16, 2021) -
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 125,000 incentive stock options to existing consultants providing investor relations services, 25,000 of which are exercisable at a price of $1.75 per share and 100,000 of which are exercisable at $2.00 per share for a period of three years and that vest equally every three months over a one-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company s stock option plan.
NervGen Pharma Corp.: NervGen Pharma Reports First Quarter 2021 Results
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its financial results for the first quarter ended March 31, 2021. We achieved several key milestones in the first quarter of 2021 including receiving clearance from the FDA to proceed with our Phase 1 clinical trial for our lead compound, NVG-291, which has now commenced in Australia, stated Paul Brennan, NervGen s President & CEO. In addition, we established an Alzheimer s Disease Scientific Advisory Board comprised of world-class scientists and clinical researchers in Alzheimer s disease and have decided to initiate a multi-dose Alzheimer s disease patient cohort as a Phase 1b addition to our clinical program. We also received Orphan Designation for NVG-291 from the European Medicines Agenc
NervGen Pharma Corp.: NervGen Pharma Grants Stock Options
Vancouver, British Columbia (Newsfile Corp. - May 7, 2021) -
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, today announced that the Company has granted 800,000 incentive stock options to an Officer of the Company exercisable at a price of $1.51 per share for a period of 10 years and that vest equally every six months over a two-year period. The options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company s stock option plan.
NervGen Pharma Corp.: NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291
nancyt@vorticom.com
212.532.2208
Follow NervGen on Twitter (@NervgenP) and LinkedIn (NervGen Pharma Corp.) for the latest news on the Company.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This news release may contain forward-looking information and forward-looking statements within the meaning of applicable Canadian and United States securities legislation. Such forward-looking statements and information herein include, but are not limited to, the Company s current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, an